20th Biennial Course in Urologic Oncology
Image
Pace
Instructor-led
Subject
Course Language
English
Advanced
Platform
HMS Continuing Education
Associated Schools
What you'll learn
Describe the optimal treatment approach to patients with oligometastatic cancers of the genitourinary tract
Explain the role of immunotherapy in the management of bladder and renal cancer
Determine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for active surveillance or other definitive management approaches
Apply Level 1 evidence on the use of novel treatment and surveillance options for patients with prostate, renal, bladder, or testicular cancer
Apply novel minimally invasive treatments for GU malignancies including prostate, bladder and kidney cancer
Use multiparametric MRI, fusion biopsy and novel markers in men at risk for prostate cancer
Course description
This is an accredited, livestreamed course offered by Brigham and Women's Hospital. This course is targeted to primary care physicians, specialty physicians, nurses, nurse practitioners, physician assistants, resident and fellow. This course may also be of interest to physicians who practice in radiation oncology, urology, radiology, pathology, oncology, and hematology, nuclear medicine, medical genetics and genomics, internal medicine,hospice and palliative medicine, healthcare education and leadership, geriatrics, and family medicine.
Select the Take Course button to view additional information on the course registration page.
*Register before Aril 12 to receive the discounted price.
You may also like
In-Person
Online Live
Price
$150 - $900
Registration Deadline
Starts Jun 10